AbbVie seeks FDA approval for etentamig to treat multiple myeloma
ABBV•AbbVie submitted a biologics license application to the U.S. FDA for etentamig to treat adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO trial, etentamig showed a 60% reduction in the risk of progression or death versus standard available therapies.
1. FDA application
AbbVie submitted a biologics license application to the U.S. FDA for etentamig to treat adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO trial showed a 60% reduction in the risk of progression or death versus standard available therapies.
